A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.

Details

Serval ID
serval:BIB_7A292F2251A7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Journal
Cancers
Author(s)
Harari A., Sarivalasis A., de Jonge K., Thierry A.C., Huber F., Boudousquie C., Rossier L., Orcurto A., Imbimbo M., Baumgaertner P., Bassani-Sternberg M., Kandalaft L.E.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
18/11/2021
Peer-reviewed
Oui
Volume
13
Number
22
Pages
5801
Language
english
Notes
Co-premier auteur avec Harrari
Publication types: Journal Article
Publication Status: epublish
Abstract
Endometrial cancer (EC) is a common gynecological malignancy and the fourth most common malignancy in European and North American women. Amongst EC, the advanced serous, p53-mutated, and pMMR subtypes have the highest risk of relapse despite optimal standard of care therapy. At present, there is no standard of care maintenance treatment to prevent relapse among these high-risk patients. Vaccines are a form of immunotherapy that can potentially increase the immunogenicity of pMMR, serous, and p53-mutated tumors to render them responsive to check point inhibitor-based immunotherapy. We demonstrate, for the first time, the feasibility of generating a personalized dendritic cell vaccine pulsed with peptide neoantigens in a patient with pMMR, p53-mutated, and serous endometrial adenocarcinoma (SEC). The personalized vaccine was administered in combination with systemic chemotherapy to treat an inoperable metastatic recurrence. This treatment association demonstrated the safety and immunogenicity of the personalized dendritic cell vaccine. Interestingly, a complete oncological response was obtained with respect to both radiological assessment and the tumor marker CA-125.
Keywords
cancer vaccines, endometrial cancer, immunotherapy, neoantigens
Pubmed
Web of science
Open Access
Yes
Create date
03/12/2021 11:53
Last modification date
13/01/2022 7:33
Usage data